| Value | ₹5,000 Cr |
|---|
BSE filing, NSE: MANKIND. Summary written from the filing by ALFA Finder's alert engine.
Mankind Pharma Ltd: key numbers
- Share price
- ₹2,490.00
- Market cap
- ₹1,02,848 Cr
- Revenue (annual)
- ₹14,278 Cr
- Net profit (annual)
- ₹1,913 Cr
- P/E (TTM)
- 45.9×Sector 46.1×
- Promoter holding
- 72.62%-0.01% QoQ
- FII holding
- 9.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mankind Pharma Ltd
All →Mankind Pharma Earnings Call Transcript: Key Takeaways
Mankind Pharma delivered robust Q2 growth driven by chronic therapies and B-Spec specialty expansion. Strong operating leverage and margin expansion offset muted consumer health performance.
- Call
- Guides 20% growth
Mankind Pharma Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹4,338 Cr (+17.3% YoY), EBITDA ₹1,175 Cr (27.1% margin), PAT ₹716 Cr (+37.7%). Domestic ex-CH +15.9%, exports +32.7%, CH +1.2%.
Mankind Pharma Results Update
Mankind Pharma reported Q2 FY27 revenue of ₹4,338 Cr, up 17% YoY, and PAT of ₹716 Cr, up 38%. EBITDA margin improved 210 bps to 27.1%.
Mankind Pharma Acquisition
Mankind Pharma's board approved amalgamation of two wholly owned subsidiaries into the parent and a step-down subsidiary merger into MCPPL. Schemes require NCLT and shareholder approvals.
Mankind Pharma Q2 FY27 Results: Net Profit ₹716.1 Cr, Up 37.7% YoY
Mankind Pharma Ltd reported revenue from operations of ₹4,338 Cr (+17.3% YoY) and net profit of ₹716.1 Cr (+37.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹716.1 Cr · +37.7% YoY
Mankind Pharma Other Announcement
Mankind Pharma Ltd filed its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Other debt & borrowing announcements
All →Fusion CX Debt & Borrowing: ₹21.85 Cr
Fusion CX lent up to Rs.21.85 Crore (USD 2.3 million) to wholly owned subsidiary Fusion BPO Services. Terms: 8.5% interest, three-year tenure, unsecured.
- Value
- ₹21.85 Cr
- Execution
- 3 years from the date of disbursal
Fusion CX Debt & Borrowing
Fusion CX Limited executed an unsecured inter-corporate term loan at 8.5% p.a. for three years with its wholly owned subsidiary Fusion BPO Services Ltd, a related party. Amount is not stated in the filing.
- Execution
- 3 years from the date of disbursal
Spandana Sphoorty Financial Debt & Borrowing: ₹0.49 Cr
Spandana paid ₹0.49 Crore of quarterly interest on its secured NCDs on 27 October 2026. The coupon rate is 10.75% on a ₹50 Crore issue.
- Value
- ₹0.49 Cr
Mangalam Worldwide Debt & Borrowing: ₹1.14 Cr
Mangalam Worldwide paid Rs. 1.14 Crore interest on its NCDs (ISIN INE0JYY07026) on 28 October 2026, net of TDS. The company confirmed timely payment under Regulation 57.
- Value
- ₹1.14 Cr
Lloyds Metals & Energy Debt & Borrowing: ₹12,370 Cr
Lloyds Metals allotted 1,300 debt securities worth about ₹12,370 Crore on 29 October 2026. Three-year coupon is SOFR plus 450 bps, secured by Virtus Lloyds share pledges.
- Value
- ₹12,370 Cr
- Execution
- 3 years
Lloyds Metals & Energy Debt & Borrowing: ₹1,235 Cr
Lloyds Metals' committee approved terms for USD 130 million senior secured notes, about Rs.1,235 Crore. The notes mature in October 2029 at SOFR plus 450 bps.
- Value
- ₹1,235 Cr